These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 27943573)

  • 1. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
    Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
    Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.
    Äyräväinen L; Leirisalo-Repo M; Kuuliala A; Ahola K; Koivuniemi R; Meurman JH; Heikkinen AM
    BMJ Open; 2017 Jan; 7(1):e011916. PubMed ID: 28143836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis.
    Kuuliala K; Kuuliala A; Koivuniemi R; Kautiainen H; Repo H; Leirisalo-Repo M
    PLoS One; 2016; 11(12):e0167975. PubMed ID: 27942004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
    Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
    Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
    Forsblad-d'Elia H; Bengtsson K; Kristensen LE; Jacobsson LT
    Rheumatology (Oxford); 2015 Jul; 54(7):1186-93. PubMed ID: 25505001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus.
    Ishida K; Shiraki K; Yoshiyasu T
    Drugs R D; 2015 Dec; 15(4):307-17. PubMed ID: 26386566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.
    Jurgens MS; Overman CL; Jacobs JW; Geenen R; Cuppen BV; Marijnissen AC; Bijlsma JW; Welsing PM; Lafeber FP; van Laar JM;
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):923-8. PubMed ID: 25504811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.
    Kawashiri SY; Nishino A; Shimizu T; Umeda M; Fukui S; Nakashima Y; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Kawakami A
    Mod Rheumatol; 2017 Mar; 27(2):252-256. PubMed ID: 27585858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.